LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) Stock Price, Quote, News and Overview
NASDAQ:LIXT - Nasdaq - US5393193017 - Common Stock - Currency: USD
LIXT Quote, Performance and Key Statistics
NASDAQ:LIXT (5/29/2025, 4:30:02 PM)
1.25
-0.09 (-6.72%)
The current stock price of LIXT is 1.25 USD. In the past month the price decreased by -0.79%. In the past year, price decreased by -46.54%.
LIXT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.07 | 327.88B | ||
| AMGN | AMGEN INC | 13.66 | 152.46B | ||
| GILD | GILEAD SCIENCES INC | 14.36 | 138.21B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.81B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.66 | 65.36B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.19B | ||
| ARGX | ARGENX SE - ADR | 98.97 | 35.47B | ||
| ONC | BEIGENE LTD-ADR | 6.32 | 26.67B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.10B | ||
| NTRA | NATERA INC | N/A | 21.58B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.47B | ||
| BIIB | BIOGEN INC | 8.39 | 19.45B |
Related stock screener links
About LIXT
Company Profile
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The company is headquartered in East Setauket, New York and currently employs 2 full-time employees. The company went IPO on 2007-09-21. The firm is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. The company is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. The LB-100 series has activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.
Company Info
LIXTE BIOTECHNOLOGY HOLDINGS
No. 2, 248 Route 25A
East Setauket NEW YORK 11733 US
CEO: John S. Kovach
Employees: 4
Phone: 13102032902
LIXTE BIOTECHNOLOGY HOLDINGS / LIXT FAQ
What is the stock price of LIXTE BIOTECHNOLOGY HOLDINGS today?
The current stock price of LIXT is 1.25 USD. The price decreased by -6.72% in the last trading session.
What is the ticker symbol for LIXTE BIOTECHNOLOGY HOLDINGS stock?
The exchange symbol of LIXTE BIOTECHNOLOGY HOLDINGS is LIXT and it is listed on the Nasdaq exchange.
On which exchange is LIXT stock listed?
LIXT stock is listed on the Nasdaq exchange.
What is LIXTE BIOTECHNOLOGY HOLDINGS worth?
LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) has a market capitalization of 3.35M USD. This makes LIXT a Nano Cap stock.
How many employees does LIXTE BIOTECHNOLOGY HOLDINGS have?
LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) currently has 4 employees.
What are the support and resistance levels for LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) stock?
LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) has a support level at 1.22 and a resistance level at 1.33. Check the full technical report for a detailed analysis of LIXT support and resistance levels.
Should I buy LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LIXT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LIXT, evaluating the profitability, health, valuation and growth aspects
- LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) Sales and EPS estimates to see what analysts future expectations are.
- LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) Insider and Institutional Ownership to learn about the owners and their transactions.
- LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) Stock Chart to make your own analysis
- LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) Latest news and press-releases to stay up to date.
Does LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) stock pay dividends?
LIXT does not pay a dividend.
When does LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) report earnings?
LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of LIXTE BIOTECHNOLOGY HOLDINGS (LIXT)?
LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.45).
What is the Short Interest ratio of LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) stock?
The outstanding short interest for LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) is 0.9% of its float. Check the ownership tab for more information on the LIXT short interest.
LIXT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to LIXT. When comparing the yearly performance of all stocks, LIXT is a bad performer in the overall market: 85.72% of all stocks are doing better.
LIXT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LIXT. LIXT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LIXT Financial Highlights
Over the last trailing twelve months LIXT reported a non-GAAP Earnings per Share(EPS) of -1.45. The EPS increased by 39.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -219.54% | ||
| ROE | -286.79% | ||
| Debt/Equity | 0 |